Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Obstructive Shock

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    10 result(s) found for: Obstructive Shock. Displaying page 1 of 1.
    EudraCT Number: 2009-017081-23 Sponsor Protocol Number: CPRC2009 - OPTIMA CC Start Date*: 2010-03-22
    Sponsor Name:Centre Hospitalier Universitaire de Nancy
    Full Title: Optimisation du traitement du choc cardiogénique. Etude pilote physiopathologique ouverte multicentrique comparant l’efficacité et la tolérance de l’adrénaline et la noradrénaline (Optima CC)
    Medical condition: choc cardiogénique
    Disease: Version SOC Term Classification Code Term Level
    12.1 10007625 Cardiogenic shock LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2022-000179-38 Sponsor Protocol Number: ESR-21-21168 Start Date*: 2022-04-28
    Sponsor Name:Bispebjerg Hospital
    Full Title: Effects of blocking TSLP on airway inflammation and the epithelial immune-response to exacerbation triggers in patients with COPD A randomized double-blind, placebo-controlled trial of tezepelumab
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10009032 Chronic obstructive lung disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-004033-42 Sponsor Protocol Number: MKI102428 Start Date*: 2007-11-22
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A 12-week, randomised, double-blind, placebo-controlled study to assess the anti-inflammatory activity, efficacy and safety of GW856553 in subjects with chronic obstructive pulmonary disease (COPD).
    Medical condition: Chronic obstructive pulmonary disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) DE (Completed) EE (Completed) FI (Completed) LT (Completed) SI (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-004429-97 Sponsor Protocol Number: GS-US-361-1157 Start Date*: 2015-03-24
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of GS-6615 on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy
    Medical condition: Subjects with symptoms (NYHA Class ≥ II dyspnea or CCS Class ≥ II angina) due to hypertrophic cardiomyopathy (defined by standard criteria as a maximal LV wall thickness of ≥ 15 mm in the absence o...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10020871 Hypertrophic cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) NL (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-001302-30 Sponsor Protocol Number: ACOVACT Start Date*: 2020-04-15
    Sponsor Name:Medical University of Vienna
    Full Title: A multicenter, randomized, active controlled, open label, platform trial on the efficacy and safety of experimental therapeutics for patients with COVID-19 (caused by infection with severe acute re...
    Medical condition: Infection with SARS-COV-2 (=COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10035737 Pneumonia viral PT
    21.1 100000004855 10003083 ARDS LLT
    20.0 10021881 - Infections and infestations 10038700 Respiratory infection LLT
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002156-84 Sponsor Protocol Number: 63623872FLZ3001 Start Date*: 2018-05-08
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, a...
    Medical condition: Influenza A Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10022002 Influenza A virus infection LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) LV (Prematurely Ended) LT (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) SK (Prematurely Ended) BE (Completed) CZ (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-005537-35 Sponsor Protocol Number: E5564-G000-301 Start Date*: 2006-08-30
    Sponsor Name:Eisai Limited
    Full Title: ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients with Severe Sepsis
    Medical condition: Severe Sepsis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10040047 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Completed) AT (Completed) CZ (Completed) ES (Completed) DE (Completed) PT (Prematurely Ended) IT (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-000296-21 Sponsor Protocol Number: APHP191110 Start Date*: 2020-04-09
    Sponsor Name:ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (AP-HP)
    Full Title: Rapid rEcognition of COrticosteroid Resistant or sentive Sepsis RECORDS A Multicentre Concealed‐Allocation Multi-arms Blinded Randomized Controlled Trial to Identify the Best Sepsis Population for ...
    Medical condition: Patients admitted to the ICU proven or suspected infection as the main diagnosis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10040050 Sepsis NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002512-40 Sponsor Protocol Number: 201023 Start Date*: 2016-12-05
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Phase II, global, randomized study to evaluate the efficacy and safety of Danirixin (GSK1325756) co-administered with a standard-of-care antiviral (oseltamivir), in the treatment of adults hospit...
    Medical condition: Hospitalized influenza
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) NL (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-003942-35 Sponsor Protocol Number: APHP200018 Start Date*: 2021-04-27
    Sponsor Name:Assistance Publique - Hôpitaux Paris
    Full Title: HydrOcortisone and fludRocortisoNe for critical ILLness-related corticosteroid insufficiency
    Medical condition: Critically ill patients with a SOFA score (SOFA; Sequential Organ Failure Assessment) ≥ 6, for at least 6 consecutive hours, suffering from CIRCI, to the notable exception of patients with septic s...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10018065 - General disorders and administration site conditions 10077264 Critical illness PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 20:24:42 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA